Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | MMP1 | P03956 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8053183 | 0.90 | PDE4B (0.66) | MAPTPDE4BNPC1RAB9AMMP1 | |
| SCHEMBL5111949 | 0.86 | MAPT (0.58) | MAPTPDE4BNPC1RAB9AMMP1 | |
| SCHEMBL7105242 | 0.86 | MAPT (0.48) | MAPTPDE4BNPC1RAB9AMMP1 | |
| SCHEMBL16552644 | 0.85 | MMP1 (0.76) | MAPTPDE4BNPC1RAB9AMMP1 | |
| SCHEMBL3830886 | 0.81 | HDAC3 (0.61) | MAPTPDE4BNPC1RAB9AMMP1 | |
| SCHEMBL14536244 | 0.81 | TAS1R3 (0.59) | MAPTPDE4BNPC1RAB9AMMP1 | |
| SCHEMBL11531236 | 0.81 | MMP1 (0.59) | MAPTNPC1RAB9AMMP1TRPA1 | |
| SCHEMBL10745082 | 0.81 | MAPT (0.53) | MAPTPDE4BNPC1RAB9AMMP1 | |
| SCHEMBL10745086 | 0.81 | MAPT (0.53) | MAPTPDE4BNPC1RAB9AMMP1 | |
| SCHEMBL4082864 | 0.81 | PDE4B (0.86) | MAPTPDE4BNPC1RAB9AMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109384766-B | Quinoline compound and preparation method and application thereof | 广东环境保护工程职业学院 | 2021-02-09 | — | — | CN | claimed |
| CN-109627232-B | Quinoline compound and preparation method and application thereof | 广东环境保护工程职业学院 | 2021-02-09 | — | — | CN | claimed |
| US-20250326746-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2025-10-23 | — | — | US | disclosed |
| US-12234231-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2025-02-25 | — | — | US | disclosed |
| EP-4392422-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-118103368-A | EIF4E inhibitors and uses thereof | 皮克医疗公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| WO-2023028235-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2023-03-02 | — | — | WO | disclosed |
| CN-109384766-B | Quinoline compound and preparation method and application thereof | 广东环境保护工程职业学院 | 2021-02-09 | — | — | CN | disclosed |
| CN-109627232-B | Quinoline compound and preparation method and application thereof | 广东环境保护工程职业学院 | 2021-02-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326746-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | MAPT 2231/4885PDE4B 1760/4885NPC1 2317/4885 |
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | MAPT 2231/4885PDE4B 1760/4885NPC1 2317/4885 |
| US-12234231-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | MAPT 2231/4885PDE4B 1760/4885NPC1 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.